Impact of acute covid-19 on cardiac function in the long term: a systematic review
DOI:
https://doi.org/10.21527/2176-7114.2025.50.16375Keywords:
Biomarkers, Troponin, Brain Natriuretic Peptide, Myocardium, COVID-19Abstract
The present study aimed to evaluate the relationship between elevated biomarkers due to COVID-19 infection and possible permanent damage to the heart muscle. This is a systematic review including studies with eligible randomized clinical trials and case-control studies. Papers’ eligibility criteria were adults diagnosed and treated for COVID-19 and assessment of cardiac biomarkers during the acute phase of COVID-19 infection, with symptoms or not, without previous structural or functional changes related to the cardiovascular system and who, after a minimum of after 30 days, cardiac structural assessment was obtained through imaging tests, either echocardiogram or cardiac magnetic resonance. The findings were not robust when analyzing the association between the elevation of secondary cardiac biomarkers to COVID-19 and the presence of late cardiac sequelae. Based on the cost-effectiveness ratio for adopting such strategy, it becomes unjustifiable to perform it routinely in the Brazilian Unified Health System. It is more appropriate and less costly to adopt health promotion strategies, individualized attention, multidisciplinary therapeutic approach, frequent clinical surveillance and specialized assessment when affected by COVID- 19, reducing damage caused to the cardiocirculatory system, minimizing spending on public health exams and better effectiveness in collective health with care practices.
References
1. Tanni SE, Silvinato A, Floriano I, Bacha HA, Barbosa AN, Bernardo WM. Uso de remdesivir em pacientes com COVID-19: revisão sistemática e meta-análise. J Bras Pneumol. 2022;48:e20210393.
2. Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666–87.
3. Gao YP, Zhou W, Huang PN, Liu HY, Bi XJ, Zhu Y, et al. Normalized Cardiac Structure and Function in COVID-19 Survivors Late After Recovery. Front Cardiovasc Med. 2021;8:756790.
4. Zhao Y, Patel J, Huang Y, Yin L, Tang L. Cardiac markers of multisystem inflammatory syndrome in children (MIS-C) in COVID-19 patients: A meta-analysis. Am J Emerg Med. 2021;49:62–70.
5. Sabanoglu C, Inanc IH, Polat E, Peker SA. Long-term predictive value of cardiac biomarkers in patients with COVID-19 infection. Eur Rev Med Pharmacol Sci. 2022;26(17):6396–403.
6. Pelà G, Goldoni M, Cavalli C, Perrino F, Tagliaferri S, Frizzelli A, et al. Long-Term Cardiac Sequelae in Patients Referred into a Diagnostic Post-COVID-19 Pathway: The Different Impacts on the Right and Left Ventricles. Diagn Basel Switz. 2021;11(11):2059.
7. Eka Ginanjar, Valerie Hirsy Putri. Elevation of Cardiac Biomarkers in COVID-19 As a Major Determinant for Mortality: A Systematic Review Tracy Anabella Hermansyah, Acta Med Indones. 2021;53(4):385-396.
8. Raymond P, Ian H, Michael AL, Emir Y, Rachel V, Antonia AL, et al. Elevated De Ritis Ratio Is Associated With Poor Prognosis in COVID-19: A Systematic Review and Meta-Analysis, Front Med (Lausanne). 2021;22:8:676581.
9. Puntmann VO, Martin S, Shchendrygina A, Hoffmann J, Ka MM, Giokoglu E, et al. Long-term cardiac pathology in individuals with mild initial COVID-19 illness. Nat Med.2022;28(10):2117–23.
10. Kotecha T, Knight DS, Razvi Y, Kumar K, Vimalesvaran K, Thornton G, et al. Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. Eur Heart J. 2021;42(19):1866–78.
11. Van den Heuvel FMA, Vos JL, van Bakel B, Duijnhouwer AL, van Dijk APJ, Dimitriu-Leen AC, et al. Comparison between myocardial function assessed by echocardiography during hospitalization for COVID-19 and at 4 months follow-up. Int J Cardiovasc Imaging. 2021;37(12):3459–67.
12. Joy G, Artico J, Kurdi H, Seraphim A, Lau C, Thornton GD, et al. Prospective Case-Control Study of Cardiovascular Abnormalities 6 Months Following Mild COVID-19 in Healthcare Workers. Jacc Cardiovasc Imaging. 2021;14(11):2155–66.
13. Myhre PL, Heck SL, Skranes JB, Prebensen C, Jonassen CM, Berge T, et al. Cardiac pathology 6 months after hospitalization for COVID-19 and association with the acute disease severity. Am Heart J. 2021;242:61–70.
14. Huang L, Zhao P, Tang D, Zhu T, Han R, Zhan C, et al. Cardiac Involvement in Patients Recovered From COVID-2019 Identified Using Magnetic Resonance Imaging. Jacc Cardiovasc Imaging. 2020;13(11):2330–9.
15. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(11):1265–73.
16. Italia L, Ingallina G, Napolano A, Boccellino A, Belli M, Cannata F, et al. Subclinical myocardial dysfunction in patients recovered from COVID-19. Echocardiogr Mt Kisco N. 2021;38(10):1778–86.
17. Gul M, Ozyilmaz S, Bastug Gul Z, Kacmaz C, Satilmisoglu MH. Evaluation of cardiac injury with biomarkers and echocardiography after COVID-19 infection. J Physiol Pharmacol Off J Pol Physiol Soc. 2022;73(1).
18. The COVID Heart—One Year After SARS-CoV-2 Infection, Patients Have an Array of Increased Cardiovascular Risks | Infectious Diseases | JAMA | JAMA Network [Internet]. Accessed December 12 2023. Available at: https://jamanetwork.com/journals/jama/fullarticle/2789793
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Revista Contexto & Saúde
This work is licensed under a Creative Commons Attribution 4.0 International License.
By publishing in Revista Contexto & Saúde, authors agree to the following terms:
The works are licensed under the Creative Commons Atribuição 4.0 Internacional (CC BY 4.0) license, which allows:
Share — to copy and redistribute the material in any medium or format;
Adapt — to remix, transform, and build upon the material for any purpose, including commercial.
These permissions are irrevocable, provided that the following terms are respected:
Attribution — authors must be properly credited, with a link to the license and indication of any changes made.
No additional restrictions — no legal or technological measures may be applied that restrict the use permitted by the license.
Notes:
The license does not apply to elements in the public domain or covered by legal exceptions.
The license does not grant all rights necessary for specific uses (e.g., image rights, privacy, or moral rights).
The journal is not responsible for opinions expressed in the articles, which are the sole responsibility of the authors. The Editor, with the support of the Editorial Board, reserves the right to suggest or request modifications when necessary.
Only original scientific articles presenting research results of interest that have not been published or simultaneously submitted to another journal with the same objective will be accepted.
Mentions of trademarks or specific products are intended solely for identification purposes, without any promotional association by the authors or the journal.
License Agreement (for articles published from September 2025): Authors retain copyright over their article and grant Revista Contexto & Saúde the right of first publication.
